QuantuMDx Group

QuantuMDx manufactures molecular diagnostic platforms and assays for infectious diseases, delivering rapid multiplex PCR testing at the point of care. Its Q-POC platform is a portable, rapid PCR diagnostic system that delivers results in approximately 30-35 minutes, with CE-IVD marking and sophisticated software algorithms that remove complicated result interpretation. The growing assay portfolio includes tests for SARS-CoV-2, Flu A/B and RSV respiratory panels, sexually transmitted infections, and antimicrobial resistance markers. The platform supports laboratory information system connectivity for seamless test record management. QuantuMDx has established distribution partnerships with Menarini for UK and France and Sansure Biotech for China and and Southeast Asia, and has been included on Public Health England's Microbiology Framework. The company has received the Outstanding Achievement Award at the Medilink Healthcare Business Awards and and Special Recognition at the Med-Tech Innovation Awards. Founded in 2008 and headquartered in Newcastle Upon Tyne, United Kingdom, the company has raised approximately $57.3M in Series D funding from investors including Adjuvo, British Business Bank, 3B Future Health Fund, and WG Partners.